Exeliom Biosciences is a clinical-stage immunotherapy company developing a first-in-class oral innate immune modulator designed to enhance the efficacy and durability of immune checkpoint inhibitors (ICIs). Its lead asset, EXL01, selectively activates the non-canonical NOD2–CARD9 signaling axis, reprogramming tumor-associated macrophages from an immunosuppressive to an antigen-presenting, T-cell–supportive state.

By restoring upstream myeloid competence, EXL01 addresses a central bottleneck in immuno-oncology: resistance driven by dysfunctional innate immunity. Preclinical and translational data demonstrate enhanced interferon signaling, improved antigen presentation, and deeper, more durable ICI responses without triggering systemic inflammation.

EXL01 is currently being evaluated in a randomized Phase II trial in first-line advanced gastric cancer in combination with nivolumab and chemotherapy. Additional expansion studies are ongoing in renal cell carcinoma, hepatocellular carcinoma, and NSCLC, across Europe and the United States.

Beyond oncology, EXL01 is being developed in other indications, including Crohn’s disease, and infectious disease, where preliminary clinical efficacy signals have been observed.

With patent protection through 2044, a scalable GMP manufacturing platform, and a clear registrational pathway in oncology, Exeliom Biosciences offers partners a differentiated, first-in-class strategy to extend and defend ICI franchises in a post–patent cliff landscape.